Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03617458 · ClinicalTrials.gov registry record · Phase 2
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT03617458: Completed Phase 2 study, sponsored by Vanderbilt University Medical Center.
NCT03617458 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 73 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03617458, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health Organization (WHO) functional class in humans with pulmonary artery hypertension (PAH).
Primary Outcome
The change in meters walked for the six-minute walk distance from baseline to week 12
Interventions
- DRUG Placebo
- DRUG Metformin
- DEVICE mHealth Intervention
- DEVICE Usual Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2025-08-19 |
| Phase | Phase 2 |
What the finished NCT03617458 record still lists
NCT03617458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03617458 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03617458 about?
NCT03617458 is a clinical study titled "Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension". The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health Organization (WHO) functional class in humans with pulmonary artery hyperten...
What is the current status of trial NCT03617458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2018-08-23. Estimated completion is 2025-08-19.
What interventions are being tested in trial NCT03617458?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), mHealth Intervention (DEVICE), Usual Care (DEVICE).
Who is sponsoring clinical trial NCT03617458?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03617458's enrollment target sits among peer trials
73 924th of 2000 higher than 1,076 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI